Subscribe to RSS
DOI: 10.1055/a-2740-8916
Sex Moderates the Fibrinogen-mediated Pathways between Cardiometabolic Factors and Lower Ankle Brachial Index: A Moderated-mediation Analysis
Authors
Abstract
This study aimed to evaluate whether fibrinogen (FGN) and intercellular adhesion molecule-1 (ICAM-1) mediate the associations between multiple risk factors and the ankle–brachial index (ABI), and to determine whether these associations and mediations differ by sex. We analyzed biomarker data from the Midlife in the United States (MIDUS 3, 2017–2022) study using bias-corrected bootstrapped moderated-mediation models. The analysis assessed the mediating roles of FGN and ICAM-1 in the relationship between seven predictors—body mass index (BMI), low-density lipoprotein (LDL), systolic blood pressure (SBP), age, HbA1c, smoking, and statin use—and ABI. Sex was specified as a moderator, and all continuous covariates were mean-centered. After excluding inapplicable cases, 708 participants were included, with a slight predominance of women (56.6%) and a mean age of 66.2 years (SD = 9.7). In men, FGN fully mediated the association between HbA1c and ABI (coefficient per +5% HbA1c = −0.02; 95% CI: −0.045 to −0.005), partially mediated the negative association between age and ABI (coefficient per +10 years = −0.004; 95% CI: −0.01 to −0.0001), and partially mediated the inverse association between BMI and ABI (coefficient per +10 kg/m2 = −0.01; 95% CI: −0.02 to −0.001), despite a positive total effect of BMI on ABI (coefficient per +10 kg/m2 = 0.05; 95% CI: 0.01 to 0.08). Additionally, FGN mediated (indirect-only mediation) the associations of LDL and smoking history with ABI (coefficient per +30 mg/dL LDL = −0.006; 95% CI: −0.011 to −0.001; coefficient for smoking history = 0.01; 95% CI: 0.001 to 0.02). Among women, only SBP predicted a lower ABI without evidence of mediation (coefficient per +10 mm Hg = −0.01; 95% CI: −0.02 to −0.002). Unexpectedly, higher LDL levels were associated with higher ABI (coefficient per +30 mg/dL = 0.03; 95% CI: 0.01 to 0.04). ICAM-1 showed no significant mediation in either sex. Statin use was not associated with ABI, FGN, or ICAM-1 levels. These findings underscore the importance of investigating sex-specific differences in the pathophysiology and management of peripheral arterial disease (PAD).
Declaration of GenAI Use
Authors used AI tool (ChatGPT) solely to enhance the readability and language of the manuscript. After utilizing the tool, the authors thoroughly reviewed and edited the content as needed and have full responsibility for the final published article.
Contributors' Statement
L.A. contributed to conceptualization, data acquisition, formal analysis, project administration and supervision. R.H., I.A., A.E., L.E.A. reviewed relevant literature, identified gaps in current knowledge, provided critical input in formulating the research objectives and overall study concept, and drafted sections of the original manuscript linking the literature to the study rationale. D.M., N.A.A., A.M.H., M.A., MA, NFA, and JA interpreted the study results, emphasized the significance of the findings within the context of existing literature, and drafted the sections addressing study implications and related content. All authors validated the results, reviewed and approved the final version of the manuscript, and are accountable for all aspects of the work. The sequence of author's names was based on their scientific contributions and was approved by all authors.
Ethical Approval
This study represents a secondary analysis of publicly available MIDUS data. All MIDUS study protocols were approved by the Institutional Review Board of the University of Wisconsin–Madison.
Publication History
Received: 26 September 2025
Accepted: 06 November 2025
Article published online:
26 November 2025
© 2025. International College of Angiology. This article is published by Thieme.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Mukherjee D, Cho L. Peripheral arterial disease: considerations in risks, diagnosis, and treatment. J Natl Med Assoc 2009; 101 (10) 999-1008
- 2 Yuan S, Damrauer SM, Larsson SC. Alcohol, liver disease, and peripheral arterial disease: epidemiology, mechanisms, and clinical implications. Arterioscler Thromb Vasc Biol 2025; 45 (09) 1493-1504
- 3 Yang SL, Zhu LY, Han R, Sun LL, Li JX, Dou JT. Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes 2017; 9 (02) 133-140
- 4 Wang W, Zhao T, Geng K, Yuan G, Chen Y, Xu Y. Smoking and the pathophysiology of peripheral artery disease. Front Cardiovasc Med 2021; 8: 704106
- 5 Kozak M, Poredoš P, Blinc A, Kaja Ježovnik M, Poredoš P. Peripheral arterial disease in women. Vasa 2024; 53 (06) 366-370
- 6 Quan X, Xiong H, Liu X. et al. Diagnosis models to predict peripheral arterial disease: a systematic review and meta analysis. Sci Rep 2025; 15 (01) 26661
- 7 Deng L, Du C, Liu L. et al. Forecasting the global burden of peripheral artery disease from 2021 to 2050: a population-based study. Research (Wash DC) 2025; 8: 0702
- 8 Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther 2019; 2019: 8295054
- 9 Kohn CG, Alberts MJ, Peacock WF, Bunz TJ, Coleman CI. Cost and inpatient burden of peripheral artery disease: findings from the National Inpatient Sample. Atherosclerosis 2019; 286: 142-146
- 10 Hawkins KE, Valentine RJ, Duke JM, Wang Q, Reed AB. Ankle-brachial index use in peripheral vascular interventions for claudication. J Vasc Surg 2022; 76 (01) 196-201
- 11 Criqui MH, Matsushita K, Aboyans V. et al; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation 2021; 144 (09) e171-e191
- 12 Aboyans V, Criqui MH, Abraham P. et al; American Heart Association Council on Peripheral Vascular Disease, Council on Epidemiology and Prevention, Council on Clinical Cardiology, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126 (24) 2890-2909
- 13 Mazzolai L, Teixido-Tura G, Lanzi S. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024; 45 (36) 3538-3700
- 14 Ozkaramanli Gur D, Gur O, Guzel S. et al. Inflammatory mediators across the spectrum of ankle-brachial index. J Atheroscler Thromb 2019; 26 (04) 351-361
- 15 Haydinger CD, Ashander LM, Tan ACR, Smith JR. Intercellular adhesion molecule 1: more than a leukocyte adhesion molecule. Biology (Basel) 2023; 12 (05) 743
- 16 Surma S, Banach M. Fibrinogen and atherosclerotic cardiovascular diseases—review of the literature and clinical studies. Int J Mol Sci 2021; 23 (01) 193
- 17 Khan TH, Farooqui FA, Niazi K. Critical review of the ankle brachial index. Curr Cardiol Rev 2008; 4 (02) 101-106
- 18 Ryff CD, Seeman T, Weinstein M. Midlife in the United States (MIDUS 3): Biomarker Project, 2017-2022. Inter-university Consortium for Political and Social Research 2023;
- 19 Ashour L. A review of user-friendly freely-available statistical analysis software for medical researchers and biostatisticians. Res Stat 2024; 2 (01)
- 20 Hunt NJ, Kang SWS, Lockwood GP, Le Couteur DG, Cogger VC. Hallmarks of aging in the liver. Comput Struct Biotechnol J 2019; 17: 1151-1161
- 21 Fu A, Nair KS. Age effect on fibrinogen and albumin synthesis in humans. Am J Physiol 1998; 275 (06) E1023-E1030
- 22 O'Hara A, Pozin J, Darki A. et al. Glycemic control and plasma levels of pro-inflammatory and pro-thrombotic biomarkers in diabetic patients presenting with acute pulmonary embolism. Clin Appl Thromb Hemost 2023; 29: 10 760296231165058
- 23 Ashour L, Ayesh L, Jarrar Z. et al. Altered anthropometrics and HbA1c levels, but not dyslipidemia, are associated with elevated hs-CRP levels in middle-aged adults: a population-based analysis. Crit Pathw Cardiol 2025; 24 (02) e0378
- 24 Notu K, Kt J, Rajesh Lenin R, G. NK, Kumar JS. The relationship between fibrinogen and glycated hemoglobin (HbA1c) in diabetic foot ulcers. Cureus 2024; 16 (08) e67174
- 25 Green D, Foiles N, Chan C, Schreiner PJ, Liu K. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis 2009; 202 (02) 623-631
- 26 Carty CL, Heagerty P, Heckbert SR. et al. Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study. Ann Hum Genet 2010; 74 (01) 1-10
- 27 Tison GH, Ndumele CE, Gerstenblith G, Allison MA, Polak JF, Szklo M. Usefulness of baseline obesity to predict development of a high ankle brachial index (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 2011; 107 (09) 1386-1391
- 28 Tabara Y, Igase M, Setoh K. et al; J-SHIPP and Nagahama study groups. Clinical significance of an elevated ankle-brachial index differs depending on the amount of appendicular muscle mass: the J-SHIPP and Nagahama studies. Hypertens Res 2018; 41 (05) 354-362
- 29 Jazayeri MA, Waheed S, Shah Z, Parashara D, Gupta K. Impact of body mass index on the association of ankle-brachial index with all-cause and cardiovascular mortality: results from the National Health and Nutrition Examination Survey. Mayo Clin Proc Innov Qual Outcomes 2019; 3 (04) 409-417
- 30 Wilson J, Webb AJS. Systolic blood pressure and longitudinal progression of arterial stiffness: a quantitative meta-analysis. J Am Heart Assoc 2020; 9 (17) e017804
- 31 Charry D, Gouskova N, Meyer ML. et al. Arterial stiffness and contralateral differences in blood pressure: The Atherosclerosis Risk in Communities (ARIC) study. J Clin Hypertens (Greenwich) 2022; 24 (07) 878-884
- 32 Wierzchowski P, Dereziński T, Migdalski A. et al. Cross-sectional study of the ankle-brachial index and cardiovascular risk factors in postmenopausal women. Kardiol Pol 2017; 75 (05) 486-494
- 33 Kuller LH, Matthews KA, Edmundowicz D, Chang Y. Incident coronary artery calcium among postmenopausal women. Atherosclerosis 2008; 200 (02) 278-285
- 34 Kumari JA, Bhaskar MV, Sanober A. et al. Intercellular adhesion molecules as novel markers of endothelial function in patients with diabetes mellitus in the South Indian population. J Clin Sci Res 2024; 13 (04) 274-279
- 35 Widjaja NA, Caesar LA, Nova S, Ardianah E. Beyond the scale: investigating adiponectin, ICAM-1, and VCAM-1 as metabolic markers in obese adolescents with metabolic syndrome. J Obes 2023; 2023: 4574042
- 36 Brake DK, Smith EO, Mersmann H, Smith CW, Robker RL. ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice. Am J Physiol Cell Physiol 2006; 291 (06) C1232-C1239
- 37 Klein LW. Pathophysiologic mechanisms of tobacco smoke producing atherosclerosis. Curr Cardiol Rev 2022; 18 (06) e110422203389
- 38 Laivuori M, Biancari F, Sinisalo J. et al. Statin use improves survival of patients with known or suspected lower extremity artery disease on all ankle brachial index levels. Vasa 2023; 52 (01) 54-62
- 39 Westin GG, Armstrong EJ, Bang H. et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014; 63 (07) 682-690
- 40 Kumbhani DJ, Steg PG, Cannon CP. et al; REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35 (41) 2864-2872
- 41 Pollak AW, Kramer CM. LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?. Clin Lipidol 2012; 7 (02) 141-149
- 42 Vidula H, Tian L, Liu K. et al. Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. Am J Cardiol 2010; 105 (09) 1348-1352
- 43 Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014; 63 (23) 2491-2502
- 44 Lan D, Song S, Liu Y, Jiao B, Meng R. Use of batroxobin in central and peripheral ischemic vascular diseases: a systematic review. Front Neurol 2021; 12: 716778
- 45 Stangl PA, Lewis S. Review of currently available GP IIb/IIIa inhibitors and their role in peripheral vascular interventions. Semin Intervent Radiol 2010; 27 (04) 412-421
- 46 McGinigle KL, Browder SE, Strassle PD, Shalhub S, Harris LM, Minc SD. Sex-related disparities in intervention rates and type of intervention in patients with aortic and peripheral arterial diseases in the National Inpatient Sample Database. J Vasc Surg 2021; 73 (06) 2081-2089.e7
- 47 Hernandez-Vila EA. Peripheral arterial disease in women: the effect of gender on diagnosis and treatment. Tex Heart Inst J 2011; 38 (02) 154-156